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ABSTRACT
Glucocorticoids (GC) are used in almost all medical specialties, and approximately 0.5% of the general population of 
the United Kingdom receives those medications. With the increased survival of patients with rheumatological diseases, 
morbidity secondary to the use of those medications represents an important aspect of the management of our patients. 
The incidences of vertebral and non-vertebral fractures are elevated, ranging from 30% to 50% of the individuals on GC 
for over three months. Thus, osteoporosis and frailty fractures should be prevented and treated in all patients initiating 
or already on GC. There are several recommendations on this topic elaborated by several international societies, but 
consensus still lacks. Recently, the American College of Rheumatology has published new recommendations, but they are 
based on the WHO Fracture Risk Assessment Tool (FRAX®) to evaluate the risk for each individual, and, thus, cannot 
be completely used for the Brazilian population. Thus, the Committee for Osteoporosis and Bone Metabolic Disorders 
of the Brazilian Society of Rheumatology, along with the Brazilian Medical Association and the Brazilian Association of 
Physical Medicine and Rehabilitation, has elaborated the Brazilian Guidelines for Glucocorticoid-Induced Osteoporosis 
(GIO), based on the better available scientifi c evidence and/or expert experience. Method of evidence collection: The 
bibliographic review of scientifi c articles of this guideline was performed in the MEDLINE database. The search for evi-
dence was based on real clinical scenarios, and used the following keywords (MeSH terms): Osteoporosis, Osteoporosis/
chemically induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glucocorticoids/ad-
ministration and dosage, Glucocorticoids/therapeutic use, Glucocorticoids/adverse effects, Prednisone/adverse effects, 
Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological 
action, Osteoporosis/prevention & control, Calcium, Vitamin D, Vitamin D defi ciency, Calcitriol, Receptors, Calcitriol; 
1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, 
Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, 
Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder, Movement, Resistance Training, Exercise Therapy, Bone 
density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, 
Radiography, (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR 
Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, 
lactation, breast-feeding, teratogens, Children (6–12 years), adolescence (13–18 years). Grade of recommendation 
and level of evidence: A) Data derived from more consistent experimental and observational studies; B) Data derived 
from less consistent experimental and observational studies; C) Case reports (uncontrolled studies); D) Expert opinion 
without explicit critical appraisal, or based on consensus, physiological studies or animal models. Objective: To establish 
guidelines for the prevention and treatment of GIO.
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INTRODUCTION
Glucocorticoids (GC) are used in almost all medical special-
ties. Approximately 0.5% of the general population of the 
United Kingdom uses those medications, and considering 
women over the age of 55 years that percentage can reach 
1.75% (B).1 The incidence of vertebral and non-vertebral 
fractures is elevated, ranging from 30%–50% of the people 
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using GC for > 3 months (A).2 The use of GC causes bone 
mass loss, especially of trabecular bone (bone type predomi-
nating in the vertebrae), and that loss is more pronounced in 
the fi rst months of therapy. A 10%–20% loss of trabecular 
bone occurs in the fi rst six months of GC use, and, in sub-
sequent years, 2% per year. In addition, a 2%–3% loss of 
cortical bone (at greater proportion in long bones) occurs 
in the fi rst year, and then, a slow and continuous loss is 
maintained (A).2 It is worth noting that the risk of fracture 
for the same bone mineral density (BMD) is higher in GC-
induced osteoporosis (GIO) than in postmenopausal or 
senile osteoporosis (B).3
The risk of fracture depends on the GC dose. The use of 
prednisone up to 2.5 mg/day leads to a relative risk (RR) of 
1.55; at the dose of 2.5–7.5 mg/day the RR is 2.59, and at doses 
greater than 7.5 mg/day the RR reaches 5.18, all risks having 
statistical signifi cance (A).4 
A study using a population database (244,235 users of GC 
and 244,235 controls) of the United Kingdom (General Practice 
Research Database – GPRD) has assessed the risk of fractures 
in patients using GC (mean dose of prednisolone of 7.8 mg/day, 
and mean cumulative dose of 13.9 g) and has found a signifi cant 
increase in the risk of fractures, mainly vertebral fractures, as 
follows: RR of any fracture, 1.33 (95% CI; 1.29–1.38); RR of 
hip fracture, 1.61 (95% CI; 1.47–1.76); and RR of vertebral 
fracture, 2.60 (95% CI; 2.31–2.92) (B).5 
Due to the elevated frequency of GC use and the increase 
in morbidity and mortality related to its use, several recom-
mendations elaborated by various international societies have 
been described in the literature (D).6–11 However, there is no 
consensus between them. Recently, the American College of 
Rheumatology (ACR) has published a new consensus that uses 
the WHO Fracture Risk Assessment Tool (FRAX®) to evaluate 
the risk for each individual (D).12 That consensus cannot be 
completely used for the Brazilian population.
This study was aimed at elaborating a guideline based on 
the best scientifi c evidence and/or expert experience, when 
that evidence was not available. 
There are risk factors that contribute to determine whether 
a patient’s risk of developing GIO is low, medium or high. The 
major risk factors are as follows: personal history of fracture in 
adult life; history of fracture in a fi rst-degree relative; current 
smoking; and low weight (< 57 kg). The minor risk factors 
are as follows: advanced age; estrogen defi ciency (menopause 
before the age of 45 years); low calcium ingestion during 
life; inadequate physical activity; alcoholism (three or more 
alcohol units/day); recent falls; dementia; vision defi ciency; 
and poor health.
This guideline will not approach GIO in situations of 
inhaled GC use, GC pulse therapy, and transplanted patients.
1. WHAT ARE THE MINIMUM GC DOSE AND 
USE DURATION THAT INDICATE THE NEED 
FOR PREVENTION AND TREATMENT OF GIO?
The minimum GC dose that indicates risk of fracture is 5 mg/day, 
the minimum GC use duration being three months (A).2
In addition, three international guidelines (D)6,7,11 have 
also recommended that patients initiating GC (prevention) at a 
minimum dose of 5 mg/day of prednisone or equivalent for at 
least three months are at risk, and pharmacological medication 
and change in life style should be instituted. Other guidelines 
(D)8,10 have recommended that prevention at doses ≥ 7.5 mg/day. 
On the other hand, the UK Bone Research Society, the National 
Osteoporosis Society and the Royal College of Physician 
guidelines (D)9 have not specifi ed the dose.
Regarding the GC use duration, most guidelines have speci-
fi ed at least three months for patients initiating GC (prevention) 
(D).6–9 Regarding patients who are already on GC (treatment), 
some societies (D)6,11 have recommended treating GIO when 
the GC dose is ≥ 5 mg/day. The Belgian Bone Club (D)10 has 
recommended treatment when the GC dose is ≥ 7.5 mg/day. 
Other societies (D)7–9 have not specifi ed the dose for patients 
on GC (treatment).
The ACR Recommendations for Prevention and Treatment 
of GIO have specifi ed the GC dose based on the risk of bone 
loss calculated by use of FRAX® (D).12 As already mentioned, 
that risk assessment cannot be completely used in the Brazilian 
population. Prevention and treatment of GIO are recommended 
as follows: 
• Postmenopausal women and men ≥ 50 years at low risk for 
fracture (FRAX®), when using GC ≥ 7.5 mg/day;
• Postmenopausal women and men ≥ 50 years at medium 
risk for fracture (FRAX ), when using any dose of GC; 
• Postmenopausal women and men ≥ 50 years at high risk 
for fracture (FRAX®), when using any dose of GC; 
• Premenopausal women (no chance of pregnancy) and men 
< 50 years with history of fracture due to frailty and GC 
use for 1–3 months at doses ≥ 5 mg/day; 
• Premenopausal women (chance of pregnancy) with history 
of fracture due to frailty and GC use ≥ 3 months at doses 
≥ 7.5 mg/day. 
Recommendation
Patients who will initiate GC (prevention) at doses ≥ 5 mg/day 
and with estimated treatment duration ≥ 3 months should 
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receive specifi c medication for preventive treatment of GIO 
and change their life style. Similarly, patients using GC 
(treatment) at the dose of ≥ 5 mg/day of prednisone or 
equivalent should also undergo the same preventive treat-
ment for GIO (D).6 Preventive and therapeutic measures are 
indicated to all patients at high risk for GIO, regardless of 
the GC dose (D).12 Such recommendations are based on the 
fact that up to 50% of patients on GC for over three months 
have an increased risk for vertebral and non-vertebral 
fractures (more frequent) (B),5 keeping in mind that, for 
the same BMD value, patients with GIO are at greater risk 
for fractures (A).2 
2. SHOULD CALCIUM BE USED IN THE 
PREVENTION AND TREATMENT OF GIO?
Calcium and vitamin D are essential nutrients for health 
maintenance. Suffi ciency of those two nutrients is considered 
a requirement for any therapeutic intervention for osteopo-
rosis (D).6–9
Treatment regimens with calcium for preventing GIO in 
men, and pre- and postmenopausal women have shown that the 
use of calcium carbonate alone at the dose of 1,000 mg/day 
leads to a 4.3% loss of BMD at the lumbar spine in one 
year (A).13 
Premenopausal women diagnosed with lupus with a 
median 2.5-year use of GC (range: 0–20 years) have been 
studied after two years of calcium carbonate replacement 
(500 mg/day) alone or associated at the same dose with 
calcitriol (0.25 µg/day). No signifi cant difference in BMD 
between the two groups was observed, showing that both 
calcium alone and the combination of calcium and calcitriol 
preserve BMD at the lumbar spine in that population (A).14 
Premenopausal women with a chance of pregnancy should 
not use bisphosphonate.
Calcium as monotherapy is considered suffi cient to neither 
prevent nor treat GIO (D).15
Recommendation
Calcium carbonate at the dose of 1,000 mg/day alone prevents 
neither bone mass loss nor fracture in patients initiating chronic 
GC use, mainly for postmenopausal women – thus, it is not 
indicated for primary prevention (A).13 For secondary preven-
tion, there is evidence of maintenance of BMD at the lumbar 
spine of premenopausal women with both the use of calcium 
carbonate (500 mg/day) alone and associated with calcitriol 
(0.25 µg/day) (A).14 
3. WHICH VITAMIN D PRESENTATION SHOULD 
BE USED FOR PREVENTING AND TREATING GIO?
Although the term vitamin D is used to encompass both calcif-
erols (cholecalciferol and ergocalciferol) and active vitamin D 
analogues, their therapeutic profi les are very distinct. The most 
commonly used forms are the active metabolites of vitamin 
D, calcitriol (1,25-dihydroxyvitamin D) and alfacalcidol (1-α-
hydroxyvitamin D). Studies on the association of calcium and 
vitamin D have shown mixed results.
A meta-analysis comparing active vitamin D analogues (al-
facalcidol and calcitriol) and calciferol in chronic GC users has 
shown that active metabolites have signifi cantly reduced bone 
mass loss at the hip and spine with effect size (ES) of 0.43 and 
P < 0.001; differently, the use of calciferol has prevented bone 
mass loss only at the hip (A).16 In that meta-analysis, only two 
studies have assessed the effects of calcitriol on the incidence 
of fractures due to GIO. Risk reduction was non-signifi cant, 
and, so far, the non-effi cacy of vitamin D to reduce fractures 
due to GIO has been established (A).13,17
Regarding primary and secondary prevention of GIO, ac-
tive vitamin D analogues were more effective in preserving 
BMD and reducing the risk of vertebral fractures as compared 
with calciferols or calcium alone, placebo or no treatment, 
with RR = 0.35 (95% CI; 0.18–0.52). Analyzing the subgroups 
of analogues, alfacalcidol prevented fractures and calcitriol 
showed only a tendency towards a protective effect (B).18
The direct comparison of alfacalcidol and non-active vi-
tamin D showed that the active form was signifi cantly more 
effective regarding bone mass gain and spinal fracture risk 
reduction, because alfacalcidol determines a signifi cant 61% 
reduction in vertebral fractures and a 52% reduction in all ver-
tebral and combined fractures, as compared with the vitamin 
D group (B).19
Alfacalcidol at the dose of 0.25–1.0 µg/day can prevent 
bone mass reduction, providing, in addition, a protective ef-
fect on vertebral fracture. Calcitriol (0.5–1.0 µg/day) seems to 
prevent spinal bone mass loss, but it does not prevent fractures.
Recommendation
Vitamin D, in its active (alfacalcidol and calcitriol) and non-
active forms (cholecalciferol and ergocalciferol), prevents 
bone mass loss in chronic GC users (A).16 The prevention of 
bone mass loss with calciferols, however, does not reduce the 
incidence of fractures (A).13,16,17
Alfacalcidol at the dose of 0.25–1.0 µg/day prevents bone 
mass reduction and decreases the risk of fracture (vertebral or 
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non-vertebral) in chronic GC users (B).19 Monitoring calcemia 
and calciuria in patients receiving vitamin D, mainly when 
using analogues, is recommended.
4. IS THE ASSOCIATION OF CALCIUM 
AND VITAMIN D BENEFICIAL FOR THE 
PREVENTION AND TREATMENT OF GIO?
Therapeutic supplementation with calcium and vitamin D is 
considered the fi rst step in the treatment of GIO, with low 
indices of toxicity and cost. 
The association of calcium and vitamin D has signifi cantly 
improved BMD at the lumbar spine (weighted mean, 2.6; 
95% CI; 0.7–4.5) and at the radius (weighted mean, 2.5; 95% CI; 
0.6–4.4) in 33% of the patients on GC, but had no signifi cant 
effects at the femur or on the incidence of fractures (A).20 
Patients diagnosed with rheumatoid arthritis and on chronic 
use of GC have shown a statistically signifi cant benefi t with the 
association of calcium carbonate (1,000 mg/day) and vitamin D 
(500 IU/day) as compared with placebo. Patients using that as-
sociation have shown a 0.72% increase per year in bone mass at 
the lumbar spine and a 0.85% increase per year at the trochanter. 
The placebo group lost bone mass at the lumbar spine and femur 
at rates of 2% and 0.9% per year, respectively (A).21 
The combined use of calcitriol (mean dose, 0.6 µg/day) and 
calcium (calcium carbonate, 1,000 mg/day), with or without 
synthetic calcitonin (nasal spray, 400 IU/day), prevented BMD 
loss at the lumbar spine, reducing that loss from 4.3% to only 
0.2% in one year (P = 0.0035). That benefi t was observed in 
neither the femoral neck nor the distal radius (A).13
Comparing patients with GIO using the association of 
calcium carbonate (500 mg/day) with alfacalcidol (1 µg/day) 
or the same dose of calcium with vitamin D3 (1,000 IU/day), 
the fi rst therapeutic scheme led to a greater benefi t in three 
years. New vertebral fracture occurred in 9.7% of the patients 
on alfacalcidol and in 24.8% of the patients on vitamin D3, 
with a reduction in RR = 0.61 (95% CI; 0.24–0.81). There was 
no reduction in the risk of non-vertebral fractures. Assessing 
the occurrence of any new fracture, both vertebral and non-
vertebral, in three years, the fi rst medicamentous association 
had 19.4% of fractures, while for the second therapeutic 
scheme that rate was 40.65%, with a signifi cant risk reduction 
of RR = 0.52 (95% CI; 0.25–0.71; P = 0.0001) (B).19
Recommendation
The association of calcium and vitamin D is benefi cial due 
to its effi cacy in preventing bone mass loss in patients on GC 
(A).20 However, the better vitamin D form to be administered 
(calciferol, alfacalcidol, or calcitriol) remains controversial. 
So far, only the association of alfacalcidol with calcium has 
shown a signifi cant reduction in the risk of vertebral fracture, 
with no effect on non-vertebral fractures (B).19
5. WHICH CHANGES IN LIFESTYLE 
SHOULD BE PERFORMED FOR THE 
PREVENTION AND TREATMENT OF GIO?
The following risk factors are known to have a negative effect 
on bone mass even in young women on GC: smoking (B);22 high 
alcohol consumption (three or more daily units) (B);23,24 sedentary 
lifestyle (energy expenditure < 1,682 kcal/day with RR = 1.7; 
95% CI; 1.2–2.3) (B);25 risk of recurrent falls in fragile elderly 
with odds ratio (OR) = 1.38 (95% CI; 1.02–1.88) (A);26 and 
low weight (each standard deviation of weight reduction 
signifi cantly increases the risk of pathological fracture by 
19%) (B).27 
Recommendation 
Similarly to that occurring in primary osteoporosis, for the 
prevention and treatment of GIO, modifi able risk factors, such 
as smoking (B),22 alcohol consumption (< 3 daily units) (B),23 
sodium (mainly in the presence of hypercalciuria), sedentary 
lifestyle (B),25 and low weight (B),27should be removed or re-
duced. Fragile elderly require special care, because they have 
a statistically signifi cant risk of recurrent falls (A).26
6. WHICH ARE THE PHYSICAL EXERCISE 
MODALITIES RECOMMENDED FOR 
PREVENTION AND TREATMENT OF GIO?
Weight training exercises improve bone mass in children and 
adolescents and can reduce bone mass loss velocity in the 
elderly. In addition, the regular practice of physical exercises 
leads to better mobility and muscle strength, reducing the risk 
of falls (D).28,29 
The practice of physical exercises, mainly of moderate to 
high impact, is recommended for the prevention and treatment 
of postmenopausal osteoporosis (A).30 Similarly, when assess-
ing elderly over the age of 65 years not using GC, a reduction 
in the risk and frequency of falls is obtained by the practice of 
exercise, with RR = 0.83 (95% CI; 0.72–0.97) and RR = 0.78 
(95% CI; 0.71–0.86), respectively. Similar reductions with 
statistical signifi cance were also obtained with the practice of 
Tai Chi Chuan (A).31
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Nevertheless, there is no evidence regarding the role of 
physical exercise in GIO. Exercises to improve lower limb 
strength and balance are believed to be particularly important 
in those patients, in whom myopathy and the risk of falls are 
common; however, whether physical activity would improve 
GC-induced myopathy is not known (D).32
Post cardiac transplant patients on GC were divided into the 
following three groups for assessment: alendronate associated 
with resistive physical exercise; alendronate alone; and control 
without interventions. After six months the group “alendronate 
plus physical exercise” showed an improvement in bone mass 
at the lumbar spine and femur as compared with the groups 
“alendronate alone” and control, with no return to pretransplant 
levels. The group “alendronate” managed to stabilize bone 
mass loss in the fi rst two months after transplantation without 
reaching pretransplant levels, while the control group continued 
to lose bone mass (B).33 
Chronic GC users undergoing a program for osteoporosis 
specifi c care showed, by the end of 6–12 months, an improve-
ment in the BMD at the spine and whole femur associated with 
a reduction in the GC dose used, higher frequency of exercises, 
and an increase in the 25-OH vitamin D levels as compared 
with the values at the study’s beginning (B).34
A group of patients with rheumatoid arthritis, of whom 
only 9% were on GC on the occasion of the study and 11% had 
never used GC (thus, a population slightly different from that 
of usual GC users), underwent either usual physical therapy or 
weight training exercises, with high intensity and long training 
period. The bone mass loss rate at the hip was lower in the 
exercise group, which was not observed for the spine (B).35
Recommendation
Physical exercises, mainly the resistive ones with weight 
lifting, are recommended for the prevention and treatment of 
GIO (B).35 Balance exercises are also recommended, mainly 
for patients at risk for falls (D).32
7. SHOULD DENSITOMETRY BE ORDERED 
BEFORE PRESCRIBING GC (PREVENTION) 
AND AFTER, WHEN THE INDIVIDUAL 
IS ALREADY ON GC (TREATMENT)?
Spinal BMD is a signifi cant predictor of new fractures in 
patients on GC. Thus, for each reduction point in the T-Score, 
the RR of fracture is 1.85 (95% CI; 1.06–3.21) (A).4
The ACR Recommendations for the Prevention and 
Treatment of GIO have suggested performing densitometry in 
patients who will use GC (prevention) for over three months, 
at doses ≥ 5 mg/day, and in patients already on GC (treatment) 
(D).6 New ACR recommendations have suggested performing 
densitometry in any patient who will use GC (prevention) and 
in patients already on GC (treatment), regardless of the dose 
and duration of GC use (D).12
Recommendation
Patients who will use GC (prevention) for over three months, 
at doses ≥ 5 mg/day, and patients already on GC (treatment) 
should undergo densitometry prior to GC prescription (D),6 and 
later (control) for assessing the bone mass reduction degree 
and the risk of fracture (A).4
8. SHOULD IMAGE ASSESSMENT OF THORACIC 
AND LUMBAR SPINE THROUGH RADIOGRAPHY 
OR DENSITOMETRY (VFA) BE ORDERED 
PRIOR TO GC PRESCRIPTION (PREVENTION) 
AND DURING ITS USE (TREATMENT)?
Approximately 33% of patients on GC have fractures, mainly in 
the vertebrae, and only 30% of such fractures are symptomatic 
and might not be associated with low BMD (B).36 Thus, spinal 
radiography is fundamental for that diagnosis. 
The ACR Preliminary Recommendations for the Prevention 
and Treatment of GIO have specifi ed that spinal image assess-
ment should be performed by use of radiography or densitom-
etry through vertebral fracture assessment (VFA) (D).12 That 
recommendation for assessing the spine aiming at detecting 
vertebral fractures has also been suggested by the International 
Society for Clinical Densitometry (ISCD) guidelines (D).37
There are no data in the literature regarding the time for per-
forming radiography or VFA in those patients. We recommend 
that assessment should be performed prior to GC introduction, 
during the fi rst year of GC use every six months, and, later, 
every one to two years, while GC is used. 
Recommendation
Spinal radiography or VFA should be performed prior to GC 
introduction, during the fi rst year of GC use every 6 months, 
and, later, every 1–2 years, while GC is used (D).12,37 
9. WHICH T-SCORE VALUE INDICATES 
PREVENTION AND TREATMENT OF GIO IN MEN?
Similarly to previously described, men on GC therapy for time 
> 3 months should undergo bone densitometry. Previous studies 
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have shown that, among men with a fracture, 16% had BMD 
between –1 and –2.5 standard deviations (SD) (A);38 the risk 
of fracture is dose-dependent. In men using up to 2.5 mg of 
prednisone, the risk of vertebral fracture was 1.55, increasing 
to 5.18 with doses > 7.5 mg (B).39 The risk of fracture increases 
rapidly after starting corticosteroid therapy, with a signifi cant 
increase in the risk of non-vertebral fracture in the fi rst three 
months (A).40 
Recommendation
For prevention, we consider a T-Score ≤ –1 SD for men, and, 
for treatment, a T-Score ≤ –1.8 SD (A).38
10. SHOULD DENSITOMETRY BE PERFORMED 
IN CHILDREN AND ADOLESCENTS 
INITIATING GC (PREVENTION) OR 
ALREADY ON GC (TREATMENT)?
In a study with children aged 4–17 years from a British data-
bank (37,562 on GC therapy, and 345,748 not on GC therapy), 
the authors have reported that those receiving four or more 
courses of systemic GC had an OR for fracture of 1.32 (A).41 
Prednisone doses ≥ 0.16 mg/kg/day for children were consid-
ered to cause osteopenia (B).42
Children with juvenile idiopathic arthritis on 0.62 mg/
kg/day of prednisone showed an increased risk of vertebral 
fracture in 2.6 years (B).43 That study supports the recom-
mendation that, when children and adolescents are already on 
GC, densitometry should be ordered due to the risk of fracture 
(D).37,44 When children will start chronic GC use, based on 
the recommendations for adults or on the recommendations 
for children and adolescents with low bone mass secondary 
to systemic diseases (D),37 baseline bone densitometry is 
recommended prior to GC use. In such cases, lumbar spine 
and whole body (excluding the head) are the regions to be 
assessed in children and adolescents (D).37 The region of the 
hip, due to its variability, is not preferred in that analysis. The 
region of the proximal femur does not have a standard curve 
for children and adolescents. The Z-Score should be used in 
children and adolescents. The description of the T-Score should 
not appear in that exam. For children and adolescents, the 
term “low bone mass for chronological age” should be used 
when the Z-Score is ≤ –2.0 SD. The terms “osteopenia” and 
“osteoporosis” should not be used in the pediatric group based 
only on densitometric criteria (D).37,44 For low stature children 
or children with pubertal delay, the densitometric analysis to 
calculate the Z-Score should be based on stature or bone age, 
rather than on chronological age. 
The diagnosis of osteoporosis in the pediatric age group 
requires a history of clinical fracture (defi ned as at least one 
fracture of a long bone in the lower limbs, at least two fractures 
in the upper limbs or one compression vertebral fracture) as-
sociated with bone densitometry (D).37,44 
Recommendation
Densitometry should be performed in children and adolescents 
who will initiate GC therapy (prevention) at prednisone doses 
≥ 0.16 mg/kg/day, because those doses are considered to cause 
osteopenia (B),42 and in those who have already undergone four 
or more courses of systemic GC (A).41
Based on the recommendations for adults, densitometry 
should be performed in children and adolescents on GC therapy 
(treatment), before GC use and as a control, assessing lumbar 
spine and whole body (excluding the head). The terms “osteo-
penia” and “osteoporosis” should not be used for the pediatric 
age group, and Z-Score rather than T-Score should be used 
(D).37 Monitoring should be based on bone mineral content 
(BMC) rather than on BMD, because the latter considers area.
11. SHOULD ALENDRONATE/RISEDRONATE 
BE USED TO PREVENT GIO?
The positive effects of bisphosphonates on bone mass of 
patients treated with GC have been demonstrated in clinical 
studies (A).45,46 When comparing the use of alendronate (5 
or 10 mg/day) with that of placebo (maintaining calcium and 
vitamin D replacement), a 35% reduction in the RR of bone 
mass loss at the lumbar spine is observed with the use of 
alendronate, benefi ting one in every three individuals treated 
for 48 weeks (NNT = 3, with 95% CI; 2–4). However, no 
reduction in vertebral fractures is observed up to a NNT = 83 
(95% CI; from 23 to infi nite) (A).45 Alendronate at the dose 
of 10 mg/day for 72 weeks has been compared with alfacal-
cidol at the dose of 1 µg/day and has shown an increase in 
bone mass (or reduction in the risk of bone mass loss), but no 
reduction in vertebral fractures up to a NNT = 20 (95% CI, 
from 9 to infi nite) (A).47 
The use of risedronate 5 mg/day for 48 weeks (maintaining 
calcium replacement) has led to a signifi cant reduction in the 
RR of bone mass loss at the lumbar spine in men and post-
menopausal, but not premenopausal, women. A reduction in 
vertebral fractures has been observed, benefi ting one in every 
nine individuals treated for 48 weeks (NNT = 9; 95% CI; 5–55). 
At the dose of 2.5 mg/day, no benefi t has been observed. A 32% 
loss has been observed in the segment studied, but assessment 
has been performed by using intention to treat (A).46 
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The effects of that group of drugs on reducing vertebral 
fractures have also been demonstrated in controlled trials. 
When using 5 mg/day of risedronate (maintaining calcium and 
vitamin D), a reduction in the incidence of vertebral fractures 
has been identifi ed after one year of treatment (A).48 
There are no studies on the use of ibandronate for GIO.
Recommendation
The use of alendronate (5 or 10 mg/day) increases bone mass, 
benefi ting one in every three individuals treated for 48 weeks 
(A),45 but no reduction in vertebral fractures occurs (A).45,47
The use of risedronate at the dose of 5 mg/day, but not at 
2.5 mg/day, increases bone mass and reduces vertebral frac-
tures in up to 70% of the patients, benefi ting one in every nine 
individuals treated for 48 weeks (A).46 
12. SHOULD ALENDRONATE/RISEDRONATE BE 
USED TO PREVENT AND TREAT GIO IN MEN?
The benefi cial effects of alendronate for men using GC have 
been assessed in the following three subgroups of individu-
als: placebo; 5 mg of alendronate for prevention; and 10 mg 
of alendronate for treatment. After 48 weeks, increases in the 
BMD at the lumbar spine of 3% (10 mg) and 1.9% (5 mg) 
have been observed as compared with the reduction in BMD 
observed in the placebo group. A 1% increase in BMD has 
been observed at the femur for both groups on alendronate, as 
well as a reduction in BMD in the placebo group. Regarding 
fractures, a non-signifi cant reduction has been observed in both 
groups on alendronate (1.4% and 2.1%) (A).45 
The use of alendronate at the doses of 5 or 10 mg/day for 
two years in men also divided into three groups has shown 
4.29% (5 mg) and 6.29% (10 mg) increases in bone mass at 
lumbar spine. Regarding fractures, there were 6.8% in the pla-
cebo group and 0.7% in both groups on alendronate, but with 
no signifi cance. Even using alendronate at the dose of 5 mg/day 
or 10 mg/day for up to two years, no signifi cant reduction in 
the risk of fractures was observed (NNT = 16; 95% CI from 
8 to infi nite) (B).49
Regarding risedronate, men on GC have been assessed for 
one year and divided into the following three groups: placebo; 
2.5 mg of risedronate; and 5 mg of risedronate. Increases in 
BMD at the lumbar spine of 2.1% (2.5 mg) and 4.8% (5 mg) 
have been observed as compared with the reduction in BMD 
in the placebo group. At the femur, a 2.1% increase in BMD 
has been observed only in the group on 5 mg of risedronate. 
The group on 2.5 mg of risedronate has shown bone mass 
stabilization. A significant reduction of 82.4% (95% CI; 
36.6%–95.1%) in the number of fractures in the group us-
ing 5 mg/day of risedronate for one year has been observed 
(A).50 A study with men using the same bisphosphonate for 
20 months and distributed into three groups identical to those 
of the previous study has reported bone mass stabilization 
in both intervention groups and a bone mass decrease in the 
placebo group, at both the spine and the femur. Regarding 
vertebral and non-vertebral fractures, no signifi cant reduction 
has been observed (A).51
Recommendation
Alendronate at the dose of 5 or 10 mg/day can be used to 
prevent and treat GIO in men, with a reduction in bone mass 
loss, but no reduction in vertebral fractures (B).49
Risedronate at the dose of 5 mg/day increases bone mass 
and reduces vertebral fractures in as much as 82.4% of the 
male population (A).50 Bisphosphonates have no benefi ts for 
non-vertebral fractures, mainly radial fractures (A).38 
13. CAN ZOLEDRONIC ACID BE USED 
TO PREVENT AND TREAT GIO?
Zoledronic acid is a bisphosphonate, which, when administered 
through annual intravenous infusion, increases BMD and 
reduces the incidence of fractures in postmenopausal women 
after the fi rst year of treatment, with NNT = 18 (95% CI; 15–22) 
for vertebral fractures and NNT = 100 (95% CI; 63–245) for hip 
fractures (A).51 That medication, when administered within 90 
days after repair surgery for low-impact traumatic hip fracture, 
reduces mortality in patients ≥ 50 years (NNT = 26; 95% CI; 
15–92), and also reduces the risk of new fractures (NNT = 22; 
95% CI; 14–54) (A).52 However, those results cannot be trans-
ferred to the target population of this guideline.
Zoledronic acid (5 mg/single dose) has been compared with 
risedronate (5 mg/day) for individuals using at least 7.5 mg/day 
of prednisolone or equivalent for at least 12 months, replace-
ment of calcium and vitamin D being kept in both groups. The 
single intravenous infusion of zoledronic acid has been more 
effi cient than risedronate, for both GIO prevention, 1.96% bet-
ter (95% CI; 1.04–2.88; P = 0.0001), and GIO treatment, 1.36% 
better (95% CI; 0.67–2.05; P = 0.0001). After 6 and 12 months 
of treatment, BMD at the lumbar spine and hip has signifi cantly 
increased, both at the femoral head and trochanter; however, no 
signifi cant reduction in new fractures has occurred. Zoledronic 
acid has caused more adverse effects, such as infl uenza-like 
symptoms (P = 0.0038) and pyrexia (P = 0.0016), than rise-
dronate, especially three days after its infusion. Severe adverse 
effects were similar in both groups (A).53 
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Given its convenient posology, a once-a-year administra-
tion, zoledronic acid increases adherence to treatment, mainly 
in patients on polypharmacy. Improvement in adherence has 
been associated with a reduction in risk fractures (B).54 
Zoledronic acid is an alternative for individuals with gastro-
intestinal disorders that make the use of oral bisphosphonates 
diffi cult.
Recommendation
Zoledronic acid (5 mg/single dose, intravenous infusion) can be 
used to prevent and treat GIO, with a greater increase in BMD 
at both the lumbar spine and hip as compared with risedronate, 
but that increase has not shown a signifi cant reduction in new 
fractures (A).53 Its convenient posology increases adherence 
to treatment, which is associated with a reduction in the risk 
of fractures (B).54 It may be an alternative for individuals 
with gastrointestinal disorders and diffi culty in using oral 
bisphosphonates.
14. SHOULD TERIPARATIDE BE USED TO  
PREVENT AND TREAT GIO?
Teriparatide, a form of parathyroid hormone obtained by 
use of a DNA recombinant technique (PTH 1–34), is an 
anabolic agent that increases the function and reduces 
the apoptosis of osteoblasts and osteocytes, in addition 
to increasing the differentiation of pre-osteoblasts into 
osteoblasts (D).55,56 Thus, regarding pathophysiology, 
teriparatide is the ideal drug for the treatment of GIO, 
because it stimulates bone formation, an action contrary 
to that of GC on that tissue.
Teriparatide at the dose of 20 µg/day, subcutaneously, causes 
a greater increase in BMD at the lumbar spine than oral alen-
dronate does at the dose of 10 mg/day (P < 0.001). By the end 
of 18 months, the group treated with teriparatide has shown a 
signifi cantly greater gain in BMD at the spine (7.2%) than the 
group treated with alendronate (3.4%). In addition, the group 
receiving teriparatide has evolved with a lower number of ver-
tebral fractures than the group treated with alendronate after 
both 18 (NNT = 24; 95% CI; 14–83) and 36 months using the 
drug (NNT = 21; 95% CI; 12–89). The number of non-vertebral 
fractures has been similar in both groups (P = 0.36) after 18 and 
36 months (P = 0.84) (A).57,58 Comparing postmenopausal and 
premenopausal women and men, the increase in spinal BMD 
has been signifi cantly higher in postmenopausal women (7.8 
vs. 3.7%; P < 0.001) than in premenopausal women (7.0 vs. 
0.7%; P < 0.001) and in men (7.3 vs. 3.7%; P = 0.03) receiving 
teriparatide compared to alendronate (A).59 
Radiological vertebral fractures have occurred in only one 
postmenopausal woman on teriparatide and in ten patients 
on alendronate (six postmenopausal women and four men) 
(P = 0.004). Non-vertebral fractures have occurred in 12 
patients on teriparatide (nine postmenopausal women, two 
premenopausal women and one man) and in eight patients 
on alendronate (six postmenopausal women and two men) 
(P = 0.36) (A).59
Recommendation
Teriparatide at the dose of 20 µg/day, subcutaneously, should 
be considered for both prevention and treatment of GIO; it 
signifi cantly increases BMD and reduces vertebral fractures, 
but has no proved effect on non-vertebral fractures (A).57 
Because of its high cost, teriparatide is recommended when 
bisphosphonates fail (new fracture or bone mass loss in the 
presence of bisphosphonate) or are contraindicated. 
15. WHICH VARIABLES INDICATE 
PREVENTION/TREATMENT OF GIO 
IN PREMENOPAUSAL WOMEN?
The recommendations that guide the treatment of GIO based 
on BMD in postmenopausal women usually do not apply to 
premenopausal women, because the relation between bone 
mass and fracture in premenopausal women is not the same 
as that in postmenopausal women. Another aspect to be con-
sidered is the fact that fractures can occur at higher BMD in 
premenopausal women (D).60
In addition, irregular menstrual cycles, sedentary lifestyle, 
vitamin D defi ciency and/or insuffi ciency, and underlying 
infl ammatory disease are other relevant factors that should be 
always considered when assessing premenopausal patients 
with GIO. Hormonal defi ciencies should be identifi ed and 
fi xed, especially in women with amenorrhea (D).61 However, 
that population should be carefully considered due to the 
chance of pregnancy, because those medicaments can cross 
the placenta and affect the fetus, and, in addition, the effects 
of their prolonged use have not been well established in that 
population (see question 18). 
The few studies on the prevention of osteoporosis in 
premenopausal women (A),62 especially regarding GIO, have 
assessed small populations with a follow-up of 18 months, 
and have demonstrated benefi t with the use of alendronate 
associated with alfacalcidol (B).63 
Comparing the use of teriparatide (20 µg/day) for 18 
months with that of alendronate (10 mg/day) in premenopausal 
women, a signifi cant increase in BMD has been observed with 
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the use of the former (7% vs. 0.7%; P < 0.001) (A).59 Some 
experts have recommended bisphosphonates of shorter half-
life, such as risedronate, in those patients, but there is no study 
supporting such recommendation. 
The following variables should be considered in premeno-
pausal women: previous history of frailty fracture; chance of 
pregnancy; GC dose; and GC use duration. The ACR recom-
mendations for prevention and treatment of GIO regarding 
premenopausal women are as follows (D):12
• Premenopausal women (no chance of pregnancy) with 
history of frailty fracture, on GC therapy for one to three 
months: oral bisphosphonates (alendronate and risedronate) 
when the GC dose is ≥ 5 mg/day, or zoledronic acid when 
prednisone ≥ 7.5 mg/day. If the duration of GC use ≥ 3 
months, both bisphosphonates (alendronate, risedronate 
and zoledronic acid) and teriparatide can be used;
• Premenopausal women (with a chance of pregnancy) with 
history of frailty fracture, on GC therapy for ≥ 3 months: 
oral bisphosphonates (alendronate and risedronate) or 
teriparatide when the GC dose ≥ 7.5 mg/day. 
Recommendation
Non-pharmacological interventions, such as regular physical 
activity, and to avoid tobacco and alcohol use, should be rec-
ommended, even with no confi rmed evidence of GIO. Calcium 
and vitamin D supplementation should be considered because 
of the reduction in intestinal calcium resorption due to GC 
use (D).10 Studies on the treatment of GIO in premenopausal 
women are scarce, all of them with small samples and showing 
the benefi t of using teriparatide (A).59 It is worth noting the 
special care required by the use of bisphosphonates in women 
with a chance of pregnancy.
16. WHEN SHOULD THE USE OF 
BISPHOSPHONATES BE INDICATED TO PREVENT 
AND TREAT GIO IN PREMENOPAUSAL WOMEN?
There is a body of evidence published on the effi cacy and safety 
of the use of bisphosphonates for preventing and treating GIO; 
however, a few premenopausal women have been included in 
the clinical trials. The large clinical trials for preventing GIO 
by using alendronate and risedronate have shown that the ef-
fi cacy of those bisphosphonates for preventing bone mass loss 
in premenopausal women is similar when compared with that 
in the total population of the studies (A).45,46,64
A recent study has reported that zoledronic acid is ef-
fi cient in preventing and treating GIO, as compared with 
risedronate. In that study, in addition to men, 185 women (67 
premenopausal women) have been included in the zoledronic 
acid group and 183 women (66 premenopausal women), in the 
risedronate group. The responses of pre- and postmenopausal 
women have not signifi cantly disagreed (A).53
Recommendation
Although there is no clinical trial with bisphosphonates specifi -
cally designed for premenopausal women as the primary objec-
tive of treatment, there is one analysis of subgroups suggesting 
the use of bisphosphonates to prevent and treat those patients 
(A).53 However, great care should be taken with women with 
a chance of pregnancy.
17. WHEN SHOULD THE USE OF TERIPARATIDE 
BE INDICATED TO PREVENT AND TREAT 
GIO IN PREMENOPAUSAL WOMEN?
A recent clinical trial has shown the benefi ts of teriparatide 
in preventing GIO in premenopausal and postmenopausal 
women, as compared with alendronate (A).57 Comparing the 
therapeutic results of teriparatide with those of alendronate in 
patients with GIO, the increase in BMD at the lumbar spine 
has been signifi cantly higher in the teriparatide group, for both 
premenopausal (7.0 vs. 0.7%) and postmenopausal women (7.8 
vs. 3.7%). In premenopausal women, the fractures have been 
infrequent in both the teriparatide and alendronate groups (A).59 
Recommendation 
There are no clinical trials designed with the primary objective 
to assess the effect of teriparatide in premenopausal women 
for the prevention and treatment of GIO, but analyses of sub-
groups of patients treated in those conditions have shown that 
fractures are infrequent in both the teriparatide and alendronate 
groups (A).59
18. CAN THE USE OF BISPHOSPHONATES 
BE HARMFUL DURING PREGNANCY? 
Studies with animals have confi rmed that bisphosphonates 
(alendronate) cross the placenta. Maternal symptoms such as 
tremors, lethargy, dyspnea and failure of the uterine muscles 
to contract during labor have been attributed to maternal 
hypocalcemia at the end of pregnancy (D).65 Low weight and 
even fetal deaths have also been reported (D).66 In the fetus, 
the reduction in length and sectional area of the diaphysis of 
long bones has also been signifi cant as compared with that of 
the control group (D).65 
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In humans, however, there is no consistent scientifi c 
evidence about the risks of using those drugs during preg-
nancy. Case series on the use of bisphosphonates during 
pregnancy have reported no congenital malformations 
(C).67,68 However, studies of patients using pamidronate and 
zoledronic acid, with two cases of malignant hypercalcemia 
(C)69–71 and one mother with osteogenesis imperfecta, have 
reported asymptomatic fetal hypocalcemia with spontane-
ous reversion in up to 11 days of life (C).71 It is speculated 
that it might be a direct effect of bisphosphonate, or fetal 
PTH suppression due to maternal hypercalcemia in cases 
of neoplasias. 
Women exposed to bisphosphonates before pregnancy 
have shown no adverse events (C).67,68 One study assessing 
24 women who had been on alendronate up to three weeks 
before pregnancy, however, has evidenced a higher preva-
lence of low fetal weight, prematurity and a higher rate 
of spontaneous abortions than in the control group (C).68 
However, those results are highly questionable, because the 
women in the study had autoimmune diseases and 13 of them 
were on GC on the occasion of pregnancy, factors known 
to be associated with the occurrence of those unfavorable 
gestational outcomes.
The infants of women exposed to bisphosphonates before 
or during pregnancy have shown neither bone abnormality 
nor other congenital malformations (D).72 Similarly, the 
use of bisphosphonates before conception and in the fi rst 
trimester of pregnancy might not represent a substantial 
fetal risk (B).73 
Recommendation
Considering the lack of evidence about the safety of bisphos-
phonate use during pregnancy, those drugs should be carefully 
used and only in specifi c cases.
19. CAN THE USE OF BISPHOSPHONATES 
BE HARMFUL DURING LACTATION?
Regarding safety of bisphosphonate use during lactation, 
there are even fewer studies and case reports. Although se-
vere maternal hypocalcemia has been observed in bovines 
(D),74 there is no similar reports in humans. A case report of 
a women with complex regional pain syndrome, who used 
pamidronate intravenously for six months during lactation, 
has suggested that the passage of the drug into maternal 
milk is negligible, being, thus, a safe option in such cases 
(C).67 However, no consistent evidence confi rming that 
fi nding exists. 
Recommendation
Currently there is little evidence regarding the safety of 
bisphosphonate use during the reproductive age, pregnancy and 
lactation. When confronted with those situations, the physician 
should weight the risks and benefi ts of the therapeutic use of 
bisphosphonates.
20. HOW LONG BEFORE PREGNANCY SHOULD 
BISPHOSPHONATES BE SUSPENDED?
No study has answered this question properly. Some studies 
have not reported deleterious effects for women interrupting the 
use of those drugs at the time pregnancy was diagnosed (D).65 
One author has suggested that suspending bisphosphonates 
6–12 months before pregnancy would be safer.
Recommendation
Because of the lack of studies establishing a safe period of 
time for the suspension of bisphosphonates, their use should 
be interrupted as earlier as possible before pregnancy.
21. WHEN SHOULD THE USE OF 
BISPHOSPHONATES BE INDICATED TO 
PREVENT AND TREAT GIO IN CHILDREN?
There is no Z-Score value that indicates that calcium and vita-
min D should be initiated for GIO. That replacement should be 
performed at the beginning of corticoid therapy. The Z-Score 
value that indicates that bisphosphonates should be used is 
≤ –2.0 SD (D).37,44,75
Calcium alone has no effect on the treatment of GIO (A).62 
However, the use of calcium and vitamin D is indicated in such 
cases (B)76 (D).77
Bisphosphonates are not allowed for children, although 
they are used in the daily practice in specialized centers. 
Contraception is indicated for girls at reproductive age. 
Some believe that bisphosphonates provide good risk-benefi t 
(B)76,78–81 (D).82 Those drugs are not used for preventing GIO in 
children and adolescents (B).76 Their indications in children and 
adolescents for treating GIO are as follow: therapeutic failure 
with maximum doses of vitamin D and calcium; intolerance 
to vitamin D and calcium or contraindication to those drugs; 
and presence of fracture (B)76,78–81 (D).82
Recommendation 
The treatment of GIO in children should be performed with 
calcium and vitamin D (B).76 In the presence of therapeutic 
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failure with maximum doses of calcium and vitamin D, intol-
erance to calcium and vitamin D or contraindication to those 
drugs, and fracture, bisphosphonates should be used (B),78 and 
special attention should be given to contraception for girls.
22. WHEN SHOULD THE USE OF TERIPARATIDE 
BE INDICATED TO TREAT GIO IN CHILDREN?
There is no evidence for indicating teriparatide for the treat-
ment of GIO in children and adolescents. Studies have shown 
the risk for developing bone tumors in animal models treated 
with that drug. Thus, for children and adolescents, whose 
cartilage growth plate is still active, being, thus, at increased 
risk, teriparatide is contraindicated.
Recommendation
Teriparatide should not be used to treat GIO in children and 
adolescents. 
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